PubRank

Yoel Kloog

Author PubWeight™ 103.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activated K-Ras and H-Ras display different interactions with saturable nonraft sites at the surface of live cells. J Cell Biol 2002 2.62
2 Individual palmitoyl residues serve distinct roles in H-ras trafficking, microlocalization, and signaling. Mol Cell Biol 2005 2.24
3 Three separable domains regulate GTP-dependent association of H-ras with the plasma membrane. Mol Cell Biol 2004 2.09
4 Cell contact-dependent acquisition of cellular and viral nonautonomously encoded small RNAs. Genes Dev 2009 2.07
5 Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 2005 1.80
6 Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem 2004 1.76
7 A unique platform for H-Ras signaling involving clathrin-independent endocytosis. Mol Biol Cell 2007 1.73
8 Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 2005 1.73
9 Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit. Biochem J 2003 1.61
10 Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002 1.53
11 Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010 1.50
12 TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function. J Immunol 2010 1.43
13 A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 2006 1.42
14 Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol Biol Cell 2008 1.39
15 Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. Cancer Res 2004 1.36
16 K-ras nanoclustering is subverted by overexpression of the scaffold protein galectin-3. Cancer Res 2008 1.29
17 The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 2008 1.25
18 Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett 2009 1.21
19 Rac2 regulation of phospholipase C-beta 2 activity and mode of membrane interactions in intact cells. J Biol Chem 2002 1.19
20 Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2007 1.19
21 The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002 1.18
22 Galectin-3 regulates a molecular switch from N-Ras to K-Ras usage in human breast carcinoma cells. Cancer Res 2005 1.16
23 Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008 1.12
24 FRAP beam-size analysis to measure palmitoylation-dependent membrane association dynamics and microdomain partitioning of Ras proteins. Methods 2006 1.11
25 The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006 1.11
26 Intercellular transfer of oncogenic H-Ras at the immunological synapse. PLoS One 2007 1.11
27 Galectin-3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-AI/II mediated myelin phagocytosis in microglia. Glia 2008 1.10
28 p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways. Cancer Res 2010 1.08
29 Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling. Mol Cell Biol 2005 1.08
30 Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Drug Resist Updat 2005 1.06
31 Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006 1.05
32 Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007 1.05
33 Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007 1.03
34 Nonconventional trafficking of Ras associated with Ras signal organization. Traffic 2006 1.00
35 Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia. Blood 2013 0.99
36 Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget 2012 0.99
37 Oncogenic synergism between ErbB1, nucleolin, and mutant Ras. Cancer Res 2011 0.99
38 Spatiotemporal organization of Ras signaling: rasosomes and the galectin switch. Cell Mol Neurobiol 2006 0.99
39 Ras and its signals diffuse through the cell on randomly moving nanoparticles. Cancer Res 2006 0.99
40 Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol 2003 0.99
41 Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 2004 0.98
42 Trans-SILAC: sorting out the non-cell-autonomous proteome. Nat Methods 2010 0.98
43 Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006 0.95
44 Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer 2011 0.95
45 Ras and autophagy in cancer development and therapy. Oncotarget 2014 0.93
46 Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol Cancer Ther 2010 0.92
47 N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells. Eur J Immunol 2008 0.92
48 Mathematical modeling of K-Ras nanocluster formation on the plasma membrane. Biophys J 2010 0.92
49 Mucus secretion and cytoskeletal modifications in cultured nasal epithelial cells exposed to wall shear stresses. Biophys J 2008 0.92
50 New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models. J Med Chem 2009 0.90
51 H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 2010 0.89
52 Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis. J Am Soc Nephrol 2003 0.88
53 Ras inhibition enhances autophagy, which partially protects cells from death. Oncotarget 2013 0.88
54 The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway. Mol Cell Neurosci 2009 0.88
55 Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. Cell Signal 2004 0.88
56 Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. Oncotarget 2013 0.88
57 Ras oncoproteins transfer from melanoma cells to T cells and modulate their effector functions. J Immunol 2012 0.86
58 Galectin-3 mediates cross-talk between K-Ras and Let-7c tumor suppressor microRNA. PLoS One 2011 0.86
59 Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer 2011 0.86
60 Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 2008 0.85
61 Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor. J Invest Dermatol 2011 0.84
62 Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death. Oncotarget 2014 0.84
63 Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats. Mol Cancer Ther 2008 0.83
64 Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes. Oncotarget 2012 0.83
65 Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 2002 0.83
66 Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death. PLoS One 2013 0.83
67 Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading. PLoS One 2013 0.82
68 Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro. J Pharm Sci 2010 0.82
69 Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome. Immunobiology 2003 0.82
70 E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 2006 0.82
71 Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling. Mol Cancer Ther 2011 0.82
72 Inhibition of Ras attenuates the course of experimental autoimmune neuritis. J Neuroimmunol 2005 0.81
73 Ras inhibition induces insulin sensitivity and glucose uptake. PLoS One 2011 0.81
74 Ras inhibition enhances autophagy, which partially protects cells from death. Oncotarget 2013 0.80
75 The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model. J Cereb Blood Flow Metab 2003 0.80
76 The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice. J Neuroimmunol 2010 0.80
77 Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib. Oncotarget 2013 0.80
78 Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Int J Cancer 2010 0.80
79 Characterization of ERK activation in human mast cells stimulated by contact with T cells. Inflammation 2010 0.79
80 Ras inhibition attenuates pancreatic cell death and experimental type 1 diabetes: possible role of regulatory T cells. Eur J Pharmacol 2010 0.79
81 Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice. Eur J Pharmacol 2009 0.79
82 Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production. Inflammation 2012 0.79
83 Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid. Dig Dis Sci 2011 0.79
84 Novel farnesylthiosalicylate (FTS)-eluting composite structures. Eur J Pharm Sci 2009 0.79
85 Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms. Immunobiology 2005 0.79
86 Rasosomes spread Ras signals from plasma membrane 'hotspots'. Biochim Biophys Acta 2009 0.79
87 The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells. Dig Dis Sci 2007 0.78
88 Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. Arterioscler Thromb Vasc Biol 2003 0.78
89 Protein-protein-interactions in a multiplexed, miniaturized format a functional analysis of Rho GTPase activation and inhibition. Proteomics 2010 0.78
90 Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release. Inflammation 2011 0.78
91 Enhancing FTS (Salirasib) efficiency via combinatorial treatment. Biol Cell 2015 0.78
92 Mechanophysical stimulations of mucin secretion in cultures of nasal epithelial cells. Biophys J 2011 0.78
93 Motor deficits and neurofibromatosis type 1 (NF1)-associated MRI impairments in a mouse model of NF1. NMR Biomed 2010 0.77
94 Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. Biochim Biophys Acta 2008 0.77
95 Ras inhibition attenuates myocardial ischemia-reperfusion injury. Biochem Pharmacol 2009 0.77
96 Climate chamber for environmentally controlled laboratory airflow experiments. Technol Health Care 2010 0.76
97 The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One 2011 0.76
98 Prion and anti-codon usage: does infectious PrP alter tRNA abundance to induce misfolding of PrP? Med Hypotheses 2008 0.76
99 Ligand-independent regulation of ErbB4 receptor phosphorylation by activated Ras. J Cell Biochem 2006 0.75
100 Mechanisms of antiproliferative drug release from bioresorbable porous structures. J Biomed Mater Res A 2012 0.75
101 Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. Dig Dis Sci 2014 0.75
102 The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. Kidney Int 2005 0.75
103 The Ras antagonist farnesylthiosalicylic acid ameliorates experimental myocarditis in the rat. Cardiovasc Pathol 2009 0.75
104 Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats. J Neurotrauma 2007 0.75